Qiming Venture Partners is a prominent venture capital firm based in Shanghai, China, founded in 2006. With additional offices in Beijing, Suzhou, Hong Kong, and Singapore, the firm focuses on early to growth-stage investments across various sectors, including healthcare, information technology, consumer goods, mobile internet, artificial intelligence, and clean technology. Qiming Venture Partners has a strong track record, having invested in over 530 innovative companies, with more than 200 achieving successful exits through public offerings or mergers and acquisitions. The firm is recognized for its deep technical expertise and hands-on operational support, making it a preferred partner for CEOs and startups seeking to scale their operations. Its partners are often sought after as board members, reflecting their status as respected business leaders and thought leaders in the venture capital landscape.
Room3906 Jinmao Tower, 88 Century Boulevard, Shanghai 200121, China
Zhang Ao
Executive Director
Cyrus Chan
Associate
Nan Chen
Principal
David Chu
Partner
Anna French
Managing Partner
Yuxin Fu
Vice President
Jinda Gao
Principal
Kuantai Yeh
Partner
Robert Headley
Partner
Maykin Ho
Venture Partner
William Hu
Managing Partner
Duane Kuang
Founding Managing Partner
Nisa Leung
Managing Partner
Dingzheng Li
Vice President
Jing Liu
Vice President
Chang Liu
Associate
Bin Liu
Vice President
Biao Lu
Associate
Shuo Mao
Principal
Gary Rieschel
Founder and Managing Partner
Motao Sun
Vice President
Amy Tang
Venture Partner
Yi Tang
Principal
Shiyu Wang
Partner
Bonnie Wang
Principal
Rachel Wang
Venture Partner
James Wang
Venture Partner
Jing Wu
Partner
Gillian Xu
RMB funds CFO
Peter (Ming) Yin
Principal, Cleantech
Janet Yu
Partner
Yafeng Zhou
Associate
Alex Zhou
Partner
Zhiyuan Zhou
Associate
Jing-Shan Hu Ph.D
Venture Partner of Healthcare
Past deals in Early Venture Stage
Weimei Health
Series A in 2025
Weimei Health is a provider of smart solutions for medical information technology
Xi'an Dunbo Medical Equipment
Series A in 2025
Xi'an Dunbo Medical Equipment focuses on the research, development, and production of AI medical devices. The products currently under development are cardiac pacemakers and brain pacemakers, Cardiac defibrillators. Self-developed products include chips, hardware circuits, software application systems, and structural materials.
Tianhu Technology
Series A in 2024
Tianhu Technology provides drug research and development services through independent collaborative closed-loop iterations, deeply integrating AI solutions with the drug development and production process. Tianhu Technology is an innovative drug R&D company that offers high-throughput phenotypic screening and physical computing technology, as well as AI solutions that are deeply integrated into the drug R&D process.
Bytelumio
Series A in 2024
Bytelumio creates advanced all-optical networks that deliver high-speed connections of 800G and 1.6T for data centers.
Epigenic Therapeutics
Series A in 2024
Epigenic Therapeutics is a biotech firm that offers gene editing therapy.
Infinigence
Series A in 2024
Infinigence is dedicated to providing AGI computing power solutions based on its large model energy efficiency optimization tools, with the goal of resolving the challenge of efficient and unified deployment of large model algorithms to large computing power chips.
Dr.Clear Aligner
Series A in 2024
Dr.Clear is an oral invisible orthodontic solution service provider that specializes in offering safe and comfortable digital solutions for face development management and invisible dental correction for children and adolescents.
CSR Biotech
Series A in 2024
CSR Biotech is a biological research company that specializes in super-resolution imaging technologies for living cells. The company focuses on the research, development, and manufacturing of advanced imaging instruments, providing a range of services such as customized cell sample generation, high-throughput detection, and imaging studies. Additionally, CSR Biotech offers image post-processing and quantitative analysis, along with high-dimensional spatio-temporal data visualization. These services are designed to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby enhancing the capabilities of scientific exploration in the field of biotechnology.
Horizone Technologies
Series A in 2024
Horizone Technologies is membrane materials and excellent filtration solutions manufacturer focusing on the R&D and production
Silicon Yi Technology
Venture Round in 2024
Silicon Yi Technology is a biotech firm specializing in RNA nanopesticide research and development designed to target pests and diseases.
Magair Chemical
Series A in 2024
Magair Chemical is a chemical synthesis CRO that was founded by Magera Technology. It is committed to using automated and intelligent platforms to provide new drug R&D customers with a new generation of chemical synthesis CRO services, significantly shortening the delivery of chemical synthesis links in the new drug R&D cycle, and significantly reducing the costs associated with chemical synthesis, removing pharmaceutical synthesis's current reliance on manual operations.
Supermag
Series A in 2024
Suzhou Supermag Intelligent Technology Co., Ltd. (hereinafter referred to as Suci Technology) is committed to the research and development, production and sales of maglev high-speed motors. With the design authorization of magnetic levitation compressors, magnetic levitation blowers, magnetic levitation pumps, etc., it provides core components such as magnetic levitation motors, magnetic levitation bearings, magnetic levitation controllers, and displacement sensors.
Swap
Series A in 2024
Swap is a company that makes a battery interchange system that is designed to replace the traditional charging process for electric motors. The company offers an energy switching system comprised of both energy stations and handmade batteries that can be used with the assistance of a mobile application, allowing users to supply speed and timeliness to bike riders at a low cost. The company aims to support the nation's zero-emission goal by providing the revolutionized charging infrastructure
ACXEL
Series A in 2024
ACXEL Tech specializes in large area electronics, focusing on digital microfluidic cell manipulation platforms that enhance drug discovery and biological research. By transforming active pixels into precise engines, ACXEL's technology enables the rapid transport of liquid droplets, facilitating complex experimental procedures at the single-cell level. This innovative approach supports various applications, including cell line development, cell therapy, synthetic biology, and antibody therapy. The platform's high throughput and low-cost design provide clients with the ability to increase productivity and efficiency in their research efforts across chemistry, biology, and medical technology.
Sano Dynamics
Series A in 2023
Sano Dynamics is a producer of hydraulic system core components and hydraulic industrial robots.
Infinigence
Series A in 2023
Infinigence is dedicated to providing AGI computing power solutions based on its large model energy efficiency optimization tools, with the goal of resolving the challenge of efficient and unified deployment of large model algorithms to large computing power chips.
Sanegene Bio
Series A in 2023
Sanegene Bio is engaged in the development of RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. The company’s RNAi drug discovery platform focuses on effectively knocking down disease-causing genes, utilizing advanced RNA technology to ensure specific delivery of multiple RNA drugs. This innovative approach allows for targeted treatment of patients suffering from a range of conditions, including cardiovascular and metabolic diseases, immunology-related diseases, infectious diseases, and disorders affecting the central nervous system and eyes. Through its comprehensive RNAi portfolio, Sanegene Bio seeks to provide effective therapeutic solutions for challenging health issues.
Tachem
Series A in 2023
Tachem is a biotechnology company that specializes in the research, development, production, and distribution of products from the protected amino acid series.
Shennapsi Artificial Intelligence Technology
Series A in 2023
Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterol monitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
Lixin Huigan
Series A in 2023
Lixin Huigan is a full-service manufacturer of sensors and an application service provider with an emphasis on the creation of premium micro-nanosensors.
Casela
Series A in 2023
Casela is a chip and semiconductor company
Congnitact
Series A in 2023
risk prediction, diagnostic, and disease monitoring tool for dementia, aiming to detect Alzheimer's disease
CSR Biotech
Series A in 2023
CSR Biotech is a biological research company that specializes in super-resolution imaging technologies for living cells. The company focuses on the research, development, and manufacturing of advanced imaging instruments, providing a range of services such as customized cell sample generation, high-throughput detection, and imaging studies. Additionally, CSR Biotech offers image post-processing and quantitative analysis, along with high-dimensional spatio-temporal data visualization. These services are designed to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby enhancing the capabilities of scientific exploration in the field of biotechnology.
Epigenic Therapeutics
Series A in 2023
Epigenic Therapeutics is a biotech firm that offers gene editing therapy.
P0x Labs
Series A in 2023
P0x labs is the team behind Manta Network is a privacy-preserving technology operating on the Polkadot blockchain.
Manta Network
Series A in 2023
Manta Network is focused on creating a secure and interoperable digital ecosystem utilizing Zero-Knowledge technology. It operates a decentralized exchange platform designed to safeguard user privacy and prevent activity tracking. The platform is built on substrate frameworks, offering an easy-to-use and secure protocol that ensures end-to-end anonymity. With capabilities for high throughput and cross-chain interoperability, Manta Network provides customers with a reliable environment for exchanging data securely.
AskGene Pharma
Series A in 2023
AskGene Pharma is a biotechnology company focused on developing innovative cytokine prodrugs to meet critical unmet medical needs in oncology and autoimmune diseases. The firm utilizes its advanced smart kine prodrug platform to fully harness the therapeutic potential of cytokine molecules, addressing significant challenges associated with current cytokine therapies. This platform is designed to avoid systemic pharmacokinetic sinks and modulate specific immune cells within the tumor microenvironment, thereby improving safety and efficacy. By leveraging cutting-edge research and development facilities, AskGene Pharma aims to deliver next-generation therapies that offer safer and more effective treatment options for patients.
Tenpoint Therapeutics
Series A in 2023
Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals with degenerative ocular diseases. The company's innovative platform focuses on creating treatments that can be delivered directly to the eye, eliminating the need for systemic administration. This targeted approach enhances the potential for effective intervention, allowing healthcare providers to significantly improve the quality of life for patients suffering from various eye conditions. Through its commitment to advancing vision-restoring technologies, Tenpoint Therapeutics is positioned to make a meaningful impact in the field of ocular health.
Guangjing Energy
Series A in 2023
Guangjing Energy specializes in the R&D and mass production of durable, large-area perovskite solar cell modules. They develops perovskite film printing technology with independent intellectual property rights and realized the preparation of large-area perovskite components.
Puanita
Series A in 2023
Puanita is a pet medicine brand seeking development with science and technology for pets. Puanita is headquartered in China.
Thorough Future
Series A in 2023
Thorough Future specializes in the integration of advanced technology within the medical sector, focusing on enhancing diagnostic services in clinical medicine. The company leverages artificial intelligence and big data to offer intelligent diagnosis and predictive services for pathology images. This innovative approach aims to improve diagnostic accuracy and efficiency, particularly for cancer patients, by providing personalized treatment recommendations. Through its commitment to integrating cutting-edge technology into healthcare, Thorough Future seeks to transform the way medical diagnoses are conducted and treatments are tailored.
CIX Technology
Series A in 2023
CIX Technology specializes in developing advanced intelligent computing solutions, focusing on high-performance, energy-efficient general-purpose computing chips and CPUs. Utilizing ARM architecture, the company designs its products for a variety of applications, including notebooks, desktops, high-end tablets, and augmented/virtual reality systems. By enhancing processing power, CIX Technology enables enterprises to create more efficient electronics and other technological products, ultimately improving computing speed and performance across various sectors.
Houmo.AI
Series A in 2023
Houmo.AI is a semiconductor company founded in 2020 by Dr. Wu Qiang, specializing in integrated circuit storage technology tailored for artificial intelligence and high-power computing applications. The company focuses on developing intelligent computing chips that cater to the growing demand for computing power in the AI sector. By leveraging innovative technologies, Houmo.AI aims to deliver chips that offer significant performance improvements while maintaining low power consumption and affordability. This approach enables enterprises to manufacture advanced intelligent robotics and other AI-integrated electronics, ultimately striving to meet the challenges of true artificial intelligence.
Complete Omics
Series A in 2023
Complete Omics is a developer focused on multi-omics diagnostics aimed at the early detection of diseases, particularly cancer. The company specializes in personalized diagnosis and treatment, leveraging patented technologies across various omics fields. By offering precision companion diagnostics, Complete Omics enables researchers and pharmaceutical companies to conduct highly sensitive and specific health surveillance tests, facilitating improved patient outcomes through tailored medical interventions.
Zeen Health
Series A in 2023
Zeen Health is a digital therapeutics company that specializes in providing personalized mental health services through a mobile application. Founded in 2019 and headquartered in Shenzhen, China, the company utilizes artificial intelligence technology to deliver evidence-based mental health solutions. By focusing on the individual needs of users, Zeen Health aims to improve mental wellness through innovative digital approaches.
Joes Future Food
Series A in 2023
Joes Future Food engages the development, production, testing, and sales of raw and auxiliary materials for food and biological products.
Brise Pharma
Series A in 2023
Brise Pharma is a biopharmaceutical company dedicated to developing innovative drugs aimed at treating pain. The company focuses on creating highly differentiated analgesic treatments for various debilitating pain conditions, particularly targeting migraine, neuropathic, and musculoskeletal pain. By addressing significant unmet needs in pain management, Brise Pharma aims to enable healthcare providers to offer safe, effective, and accessible pain relief solutions for patients worldwide who suffer from poorly managed pain conditions.
Bioyond Tech
Series A in 2023
Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.
Qianshou
Series A in 2023
Qianshou is a dating application that helps to find the right partner for life by using artificial matchmaker service.
Deepway
Series A in 2023
Deepway is a manufacturer of smart vehicles focused on the truck freight market, offering advanced intelligent driving solutions. The company designs heavy-duty trucks characterized by low wind resistance and high-level intelligent driving capabilities. Its vehicles feature a distributed drive system with a modular design that operates on a unified hydrogen and electricity platform. This innovative approach allows the logistics industry to leverage smart freight systems, enhancing efficiency and sustainability in transportation.
Ricoton
Series A in 2023
Ricoton specializes in the development and production of medical devices aimed at treating or preventing cerebrovascular diseases. Founded in 2011 and based in Hunan, China, the company manufactures an array of intervention devices, including microcatheters, guidewires, and various tools for ischemic stroke treatment. Their product offerings feature a comprehensive three-piece set that includes a micro guide wire, micro catheter, and support catheter for vascular access, as well as a thrombectomy stent and balloon guide catheter. Ricoton's innovative solutions provide a one-stop thrombectomy option for patients, enhancing the effectiveness of cerebrovascular interventions.
TandemAI
Series A in 2023
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.
Xinchuangyuan Semiconductor
Series A in 2023
Xinchuangyuan Semiconductor is a manufacturing company of electronic equipment. Xinchuangyuan Semiconductor was founded in 2021 and was headquartered in Wuhan, China.
Swords & Dungeons
Series A in 2023
Swords & Dungeons is a developer of massively multiplayer online role-playing game (MMORPG) content, specializing in Web3 multi-chain game software. The company focuses on creating and updating interfaces for the gaming industry, offering decentralized games that provide engaging and social entertainment. By leveraging innovative technologies, Swords & Dungeons enables users to experience new types of gaming, making it a notable player in the evolving landscape of online gaming.
Biotree Technology
Series A in 2023
Biotree is a high-tech enterprise focused on the application and development of advanced research technology in the life sciences sector. It specializes in metabolomics, offering early detection and analysis services in China. The company boasts a core team with significant expertise in metabolomics, encompassing scientific research services, health testing, and industrial testing. Biotree emphasizes mass spectrometry and metabolic testing, continually innovating in metabolomics products and technologies. It holds several patents in this field and is recognized for its accomplishments in metabolomics detection and analysis. Over the years, Biotree has demonstrated consistent growth and has maintained profitability for six consecutive years, solidifying its position in the biotechnological testing and consulting services market.
Shennapsi Artificial Intelligence Technology
Series A in 2022
Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterol monitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
Veridise
Series A in 2022
Veridise is a blockchain security company that specializes in identifying and addressing vulnerabilities in various blockchain applications. Founded by a team of experienced researchers, Veridise is renowned for its expertise in auditing Zero-Knowledge Circuits, MetaMask Snaps, smart contracts, and various decentralized finance protocols. The firm employs a hybrid approach that combines traditional auditing methods with automated Web3 security tools, enabling it to uncover critical vulnerabilities that other firms may overlook. In the first half of 2023, Veridise identified over 100 high-severity bugs, demonstrating its effectiveness in enhancing blockchain security. The company also offers a comprehensive platform for automatically auditing smart contracts, allowing clients to implement formal methods for improved security and correctness in their blockchain projects.
Reunion Biotech
Series A in 2022
Reunion Biotech focuses on the research and development and industrial transformation of medical hydrogels. The company is committed to becoming an international leading hydrogel technology platform. The current pipeline includes systemic solutions for tumor radiotherapy protection, wound repair, tumor embolization, and drug delivery.
Entact Bio
Series A in 2022
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed to create enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.
BayOmics
Series A in 2022
BayOmics is a biotechnology company specializing in the commercial development of proteomics research. It focuses on the application of advanced biological and pharmaceutical technologies aimed at addressing critical illnesses. Utilizing integrated automated proteomics technology, BayOmics conducts functional proteome analyses and engages in the discovery of new drug targets. The company also supports targeted drug research and development based on micro-clinical samples. Through these efforts, BayOmics provides essential technical support to the medical industry, contributing to the advancement of treatments for cancer and other significant diseases.
Sanegene Bio
Series A in 2022
Sanegene Bio is engaged in the development of RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. The company’s RNAi drug discovery platform focuses on effectively knocking down disease-causing genes, utilizing advanced RNA technology to ensure specific delivery of multiple RNA drugs. This innovative approach allows for targeted treatment of patients suffering from a range of conditions, including cardiovascular and metabolic diseases, immunology-related diseases, infectious diseases, and disorders affecting the central nervous system and eyes. Through its comprehensive RNAi portfolio, Sanegene Bio seeks to provide effective therapeutic solutions for challenging health issues.
PureVision
Series A in 2022
PureVision focuses on developing medical devices for ophthalmology. PureVision was founded in 2022 and was headquartered in Wenzhou, Zhejiang China.
PlusLife Biotech
Series A in 2022
PlusLife Biotech, founded in 2017 and based in Guangzhou, China, focuses on creating innovative molecular diagnostic tools and gene treatment programs utilizing advanced gene technology. The company has developed a range of molecular point-of-care testing (POCT) detection cards and reagents designed for diverse applications, including human respiratory and reproductive tract infections, genotype detection, and pet disease detection. PlusLife Biotech aims to provide customers with cost-effective and user-friendly testing solutions, enhancing the accessibility and efficiency of medical diagnostics.
Bitworx
Series A in 2022
Bitworx is a company based in Chengdu, China, specializing in product development and applications that leverage advanced algorithm and chip technology for communication, sensing, and detection. Currently, Bitworx is operating in stealth mode, which indicates that it is in the early stages of its business activities and may not yet be publicly disclosing its specific projects or technologies. The focus on communication and sensing technologies suggests a commitment to innovation in fields that require precise detection and data transmission capabilities.
Soda Health
Series A in 2022
Soda Health is a healthcare technology company founded in 2021 and based in Chicago, Illinois. The company focuses on addressing health inequities by leveraging social determinants of health. It offers a technology platform designed to assist individuals in identifying, accessing, and funding the resources necessary for a healthy life. By providing a system for administering and reimbursing personalized benefits, Soda Health enables customers to effectively bridge the gap between medical claims and retail payments, ultimately promoting better health outcomes.
Dezhen Technology
Series A in 2022
Dezhen Technology provides solutions for medical institutions to help hospitals develop clinical, and scientific research management. Dezhen Technology is headquartered in Hongkou, China.
XellSmart
Series A in 2022
XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.
KouTech
Series A in 2022
KouTech develops surgical robots that can perform ophthalmic surgery, trans-gastroscopic, and general-purpose microsurgery. KouTech was founded in 2022 and was headquartered in Shanghai, China.
Deepway
Series A in 2022
Deepway is a manufacturer of smart vehicles focused on the truck freight market, offering advanced intelligent driving solutions. The company designs heavy-duty trucks characterized by low wind resistance and high-level intelligent driving capabilities. Its vehicles feature a distributed drive system with a modular design that operates on a unified hydrogen and electricity platform. This innovative approach allows the logistics industry to leverage smart freight systems, enhancing efficiency and sustainability in transportation.
GluBio Therapeutics
Series A in 2022
GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.
OPUS
Series A in 2022
OPUS develops clinically applicable tissue engineering products and treatments.
P0xeidon Labs
Series A in 2022
P0xeidon Labs focuses on building web3 privacy, creating, and deploying tools.
Auron Therapeutics
Series A in 2022
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.
Biotree Technology
Series A in 2022
Biotree is a high-tech enterprise focused on the application and development of advanced research technology in the life sciences sector. It specializes in metabolomics, offering early detection and analysis services in China. The company boasts a core team with significant expertise in metabolomics, encompassing scientific research services, health testing, and industrial testing. Biotree emphasizes mass spectrometry and metabolic testing, continually innovating in metabolomics products and technologies. It holds several patents in this field and is recognized for its accomplishments in metabolomics detection and analysis. Over the years, Biotree has demonstrated consistent growth and has maintained profitability for six consecutive years, solidifying its position in the biotechnological testing and consulting services market.
Resunbio
Series A in 2022
Resunbio provides micro-nano processing research and development precipitation. Resunbio is headquartered in Longhua, China.
Crema Finance
Series A in 2022
Crema Finance is a developer of a protocol for concentrated liquidity aimed at promoting decentralized trading. In addition to providing NFT farming, integrated aggregators, and Web3 infrastructure, the company has created a fully augmented algorithm that enables liquidity providers to increase liquidity within target price ranges, traders to swap orders with less price slippage, and developers to incorporate the company's service to improve Dapps and fortify Defi.
AskGene Pharma
Series A in 2022
AskGene Pharma is a biotechnology company focused on developing innovative cytokine prodrugs to meet critical unmet medical needs in oncology and autoimmune diseases. The firm utilizes its advanced smart kine prodrug platform to fully harness the therapeutic potential of cytokine molecules, addressing significant challenges associated with current cytokine therapies. This platform is designed to avoid systemic pharmacokinetic sinks and modulate specific immune cells within the tumor microenvironment, thereby improving safety and efficacy. By leveraging cutting-edge research and development facilities, AskGene Pharma aims to deliver next-generation therapies that offer safer and more effective treatment options for patients.
Houmo.AI
Series A in 2022
Houmo.AI is a semiconductor company founded in 2020 by Dr. Wu Qiang, specializing in integrated circuit storage technology tailored for artificial intelligence and high-power computing applications. The company focuses on developing intelligent computing chips that cater to the growing demand for computing power in the AI sector. By leveraging innovative technologies, Houmo.AI aims to deliver chips that offer significant performance improvements while maintaining low power consumption and affordability. This approach enables enterprises to manufacture advanced intelligent robotics and other AI-integrated electronics, ultimately striving to meet the challenges of true artificial intelligence.
JIIOV
Series A in 2022
JIIOV Technology is a biometric recognition solutions provider.
Tingsheng Technology
Series A in 2022
TINGSN develops Intracardiac echocardiography (ICE) catheter imaging technology designed to treat cardiac arrhythmia. In addition to ICE products, the company has developed its own heart internal catheter positioning and software algorithms and is developing China first computer surgical simulator for cardiac electrophysiology based on digital heart model.
Medmotion
Series A in 2022
Medmotion is an operator of a comprehensive sports rehabilitation clinic.
GluBio Therapeutics
Series A in 2022
GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.
WOWJOY TECHNOLOGY
Series A in 2022
WOWJOY TECHNOLOGY, based in Hangzhou, China, specializes in data-driven medical services through an internet-based platform. The company offers a range of informational technology solutions tailored for large hospital groups and their patients. Its services include integrated workstations for medical, imaging, laboratory, and pharmacy functions. By streamlining information processing procedures, WOWJOY TECHNOLOGY aims to enhance the efficiency of diagnosis, treatment, and billing in the healthcare sector.
Cencorp Automation
Series A in 2022
Cencorp Automation is a provider of process automation solutions focused on the electronics industry. The company offers a diverse range of equipment solutions including depaneling, odd-form assembly, test handling, laser marking, laser welding, and final assembly. Their innovative automation platforms are designed to enhance productivity and quality for their customers, which include leading firms in car electronics, telecommunications, and industrial electronics. By delivering tailored solutions, Cencorp Automation significantly improves the efficiency of customers' production processes.
Xiaoniao Kuaiyan
Series A in 2022
Xiaoniao Kuaiyan, headquartered in Beijing, China, offers home physical examination services that include regular health check-ups, tumor screenings, infection tests, chronic disease surveillance, and customized testing options for clients. In addition to these health services, the company also facilitates business cooperation between enterprises and provides customer service and professional training. Xiaoniao Kuaiyan is involved in formulating management procedures for quality inspection work and develops a product knowledge base to enhance its service offerings.
Ceptur Therapeutics
Series A in 2022
Ceptur Therapeutics is focused on developing innovative genetic medicines aimed at addressing diseases that currently lack effective treatments. The company utilizes its proprietary U1 Adaptor technology, which enables long-lasting and non-genotoxic silencing of disease-causing genes, particularly in challenging tissues beyond the liver and central nervous system. This technology addresses the limitations of existing gene silencing methods and holds promise for cancer treatment, allowing healthcare providers to offer new therapeutic options for patients with various types of cancers.
Axera
Series A in 2022
Axera is a high-tech semiconductor company that specializes in creating advanced artificial intelligence system-on-chips (SoCs) for various computer applications. The company's innovative chips are designed to excel in visual processing, delivering high performance while maintaining low power consumption and low latency. Axera's technology enables real-time video analysis, high-quality video capture, and efficient integration of multiple cameras, all at a competitive cost. This focus on high-integration architecture positions Axera as a key player in the semiconductor industry, catering to clients seeking efficient and effective solutions for complex visual tasks.
MKSEMI
Series A in 2022
MKSEMI is a low-power ultra-wideband (UWB) company, provides a complete high precision location solution for device OEMs and ODMs.
Ruining Bio
Series A in 2022
Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. Ruining Bio brings together various professionals in materials, chemistry, biomedical engineering, and clinical medicine.
Gemsouls
Series A in 2021
Gemsouls is a developer of an artificial intelligence platform that enables virtual characters to interact with the real world. The company aims to create an innovative experience for fans, allowing them to engage with their favorite characters and maintain lasting connections with both fictional and real-life figures. By leveraging AI technology, Gemsouls facilitates meaningful interactions, enhancing the ways individuals can relate to and enjoy their beloved characters.
Xinchuangyuan Semiconductor
Series A in 2021
Xinchuangyuan Semiconductor is a manufacturing company of electronic equipment. Xinchuangyuan Semiconductor was founded in 2021 and was headquartered in Wuhan, China.
SUPERHEXA
Series A in 2021
Superhexa is a cutting-edge hardware firm that specializes in personal consumer electronics. Superhexa was founded at October 15, 2020 by Xia Yongfeng and is located in Beijing.
Supermag
Series A in 2021
Suzhou Supermag Intelligent Technology Co., Ltd. (hereinafter referred to as Suci Technology) is committed to the research and development, production and sales of maglev high-speed motors. With the design authorization of magnetic levitation compressors, magnetic levitation blowers, magnetic levitation pumps, etc., it provides core components such as magnetic levitation motors, magnetic levitation bearings, magnetic levitation controllers, and displacement sensors.
Cubenergy Technology
Series A in 2021
Cubenergy Technology is an energy technology company specializing in energy data operation services and the integration of distributed energy storage systems. The company develops advanced Energy Management Systems that utilize data analysis to optimize the performance of energy storage systems. By focusing on efficient control mechanisms, Cubenergy Technology aims to enhance system efficiency and provide users with effective energy management solutions.
WOWJOY TECHNOLOGY
Series A in 2021
WOWJOY TECHNOLOGY, based in Hangzhou, China, specializes in data-driven medical services through an internet-based platform. The company offers a range of informational technology solutions tailored for large hospital groups and their patients. Its services include integrated workstations for medical, imaging, laboratory, and pharmacy functions. By streamlining information processing procedures, WOWJOY TECHNOLOGY aims to enhance the efficiency of diagnosis, treatment, and billing in the healthcare sector.
BUD
Series A in 2021
BUD, founded in 2019 by former Snap engineers Risa Feng and Shawn Lin, is a Singapore-based company that operates a user-generated open metaverse gaming platform. This platform connects millions of virtual worlds created by a community of approximately 9 million creators. Since its global launch in November 2021, BUD has rapidly gained popularity, ranking among the top 10 social apps in over 38 countries, including regions in North America, Southeast Asia, and South America. The platform allows users to easily customize 3D worlds through a simple drag-and-drop interface, enabling the creation and sharing of interactive experiences that range from social hangouts to competitive games. BUD has evolved into a vibrant digital social hub where users can create, play, and interact with 3D content alongside friends.
V Light
Series A in 2021
Shimmer is an app that provides companionship. Whether chatting, watching videos, playing games, or singing karaoke, it can all help in finding a chat topic.
Sanegene Bio
Series A in 2021
Sanegene Bio is engaged in the development of RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. The company’s RNAi drug discovery platform focuses on effectively knocking down disease-causing genes, utilizing advanced RNA technology to ensure specific delivery of multiple RNA drugs. This innovative approach allows for targeted treatment of patients suffering from a range of conditions, including cardiovascular and metabolic diseases, immunology-related diseases, infectious diseases, and disorders affecting the central nervous system and eyes. Through its comprehensive RNAi portfolio, Sanegene Bio seeks to provide effective therapeutic solutions for challenging health issues.
PlusLife Biotech
Series A in 2021
PlusLife Biotech, founded in 2017 and based in Guangzhou, China, focuses on creating innovative molecular diagnostic tools and gene treatment programs utilizing advanced gene technology. The company has developed a range of molecular point-of-care testing (POCT) detection cards and reagents designed for diverse applications, including human respiratory and reproductive tract infections, genotype detection, and pet disease detection. PlusLife Biotech aims to provide customers with cost-effective and user-friendly testing solutions, enhancing the accessibility and efficiency of medical diagnostics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.